H

    HOTH (HOTH)

    Official site

    BIOTECHNOLOGY

    $0.71
    -0.01 (-1.68%)

    Last updated: Aug 28, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    50%(14/28)
    Avg Surprise
    -9.59%

    Upcoming Estimates

    Mar 31, 2026
    EPS Consensus$N/A
    Revenue Consensus
    $0
    Range$0 - $0
    0 analysts
    Jun 30, 2026
    EPS Consensus$N/A
    Revenue Consensus
    $0
    Range$0 - $0
    0 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Jun 26EST
    		-N/A---
    Mar 26EST
    		-N/A---
    Dec 25
    		$-0.16$-0.10-60.00%Miss+50.0%
    Sep 25
    		$-0.30$-0.27-11.11%Miss+3.2%
    Jun 25
    		$-0.17$-0.31+45.16%Beat+29.2%
    Mar 25
    		$-0.27$-0.34+20.59%Beat+41.3%
    Dec 24
    		$-0.32$-0.43+25.58%Beat+0.0%
    Sep 24
    		$-0.31$-0.34+8.82%Beat+48.3%
    Jun 24
    		$-0.24$-0.43+44.19%Beat+57.7%
    Mar 24
    		$-0.46$-0.43-6.98%Miss+83.9%
    Dec 23
    		$-0.32$-0.51+37.25%Beat+88.8%
    Sep 23
    		$-0.60$-0.72+16.67%Beat+70.7%
    Jun 23
    		$-0.57N/A+51.10%Beat+74.8%
    Mar 23
    		$-2.86$-2.29-24.89%Miss-4.0%
    Dec 22
    		$-2.86$-2.29-24.89%Miss+18.3%
    Sep 22
    		$-2.05$-2.39+14.23%Beat+41.4%
    Jun 22
    		$-2.25$-2.37+5.06%Beat+35.7%
    Mar 22
    		$-2.75$-3.50+21.43%Beat+54.2%
    Dec 21
    		$-3.50$-3.12-12.18%Miss-250.0%
    Sep 21
    		$-3.50$-3.37-3.86%Miss+12.5%
    Jun 21
    		$-3.50$-4.25+17.65%Beat+30.0%
    Mar 21
    		$-6.00$-2.50-140.00%Miss-33.3%
    Dec 20
    		$-1.00N/A+60.00%Beat+90.5%
    Sep 20
    		$-4.00$-3.37-18.69%Miss+5.9%
    Jun 20
    		$-5.00$-3.75-33.33%Miss-53.8%
    Mar 20
    		$-4.50$-4.17-7.91%Miss-3990.9%
    Dec 19
    		$-10.50$-3.42-207.02%Miss-34900.0%
    Sep 19
    		$-4.25$-2.42-75.62%Miss-
    Jun 19
    		$-3.25$-2.75-18.18%Miss-
    Mar 19
    		$-0.11$-0.12+8.33%Beat-
    Dec 18
    		$-0.03N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-0.79EV/EBITDAN/A
    Price/FCF-1.11xFCF Yield-89.79%
    Profitability
    Profit MarginN/AOperating MarginN/A
    ROEN/AROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio3.39xQuick Ratio3.39x
    Trading Statistics
    BetaN/AAvg Volume541.69K
    52-Week HighN/A52-Week LowN/A

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.74
    SMA 20$0.77
    SMA 50$0.83
    SMA 200$0.95
    EMA 10$0.74
    EMA 20$0.76
    EMA 50$0.83
    EMA 200$0.96

    MACD

    Line: -0.03Signal: -0.04Hist: 0.00

    ADX

    ADX: 12.6+DI: 12.9-DI: 24.4

    Aroon & PSAR

    Aroon Up16.0
    Aroon Down84.0
    PSAR$0.81

    Bollinger Bands

    Upper Band$0.82
    Lower Band$0.71
    %B Position1547%(Upper)
    Band Width0.03

    RSI (14-Day)

    Neutral
    34.9

    Momentum Oscillators

    Stoch %K21.9
    Stoch %D27.9
    Williams %R-85.3
    ROC (10d)-7.1%
    Momentum-0.05
    CCI (20d)-145.5
    MFI (14d)40.4

    Volatility Measures

    ATR (14d)$0.05(7.3%)
    StdDev (20d)0.03
    Hist Vol30.4%(Moderate)

    Volume Flow

    VWAP$0.71
    OBV469.6M
    AD Line-115.0M
    CMF (20d)0.201

    Volume Metrics

    Avg Vol (20d)395.2K
    Vol Ratio0.7x
    VWMA (20d)$0.77

    Pivot Points

    R3$0.75
    R2$0.75
    R1$0.73
    Pivot Point$0.73
    S1$0.71
    S2$0.71
    S3$0.69

    Advanced Oscillators

    TSI-20.60
    Ultimate Osc62.5
    KST-98.70

    Financial Data

    QuarterMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Total Revenue$0$0$0$0$0$0$0$0$0$59,538$0$0
    Cost of RevenueN/AN/AN/AN/A$4,354N/AN/AN/AN/A$29,769$6,752$7,897
    Gross ProfitN/AN/AN/AN/A$-4,354N/AN/AN/AN/A$29,769$-6,752$-7,897
    Operating Expenses$2.65M$2.61M$4.08M$2.20M$3.48M$2.38M$2.13M$1.65M$2.16M$1.70M$2.09M$1.71M
    R&D$1.52M$1.31M$1.63M$1.04M$1.96M$1.32M$897,510$566,335$571,642$914,599$974,374$652,202
    SG&A$1.13M$1.29M$2.45M$1.16M$1.50M$1.05M$1.23M$1.08M$1.57M$783,217$1.11M$1.05M
    Operating Income$-2,648,449$-2,605,019$-4,080,663$-2,199,649$-3,476,017$-2,383,182$-2,132,253$-1,645,839$-2,159,904$-1,697,816$-2,092,980$-1,708,629
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$44,016$83,170$25,137$0$0$0$0$0$0$9,310$0$164,402
    Income Before Tax$-2,692,465$-2,688,189$-4,105,800$-2,199,476$-3,475,836$-2,382,990$-2,132,053$-1,632,474$-2,146,529$-1,702,269$-2,086,583$-1,873,031
    Income Tax Expense$0$0$0$0$0$0$0$-1,645,839$-2,054,159$-1,697$33,975$42,317
    Net Income$-2,692,465$-2,688,189$-4,105,800$-2,199,476$-3,475,836$-2,382,990$-2,132,053$-1,632,474$-2,146,529$-1,702,269$-2,086,583$-1,873,031
    EBITDA$-2,648,449$-2,605,019$-4,105,800$-2,199,479$-3,476,017$-2,383,182$-2,132,253$-1,645,839$-2,054,160$-1,702,273$-2,092,980$-1,544,227
    EBITN/AN/AN/AN/A$-3,480,371N/AN/A$-3,291,679$-4,108,318$-3,395,632$-4,185,960$-3,252,856
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about HOTH

    News

    HOTH stock trades on its latest clinical and financial update.

    Hoth Therapeutics, Inc. (HOTH) stock is being traded based on its recent clinical and financial update, according to an AD HOC NEWS report. As a micro-cap company, Hoth's stock performance is highly sensitive to progress in its therapeutic programs, development milestones, and its cash position, which influence potential dilution and trial timings. The company's focus on a narrow set of assets means that individual product updates significantly impact its operating outlook and investor expectations.

    Ad-hoc-news.de•7/21/26•
    Neutral

    Hoth Therapeutics outlines its biotech pipeline as a micro-cap player

    Hoth Therapeutics, a clinical-stage biotechnology company, is developing novel therapies for dermatology and central nervous system disorders. As a micro-cap player, it focuses on in-licensing and developing drug candidates, balancing multiple programs to mitigate risk and relying on external financing for operations. The company's stock is characterized by high volatility due to its early stage and reliance on trial data and financing events.

    AD HOC NEWS•7/7/26•
    Neutral

    Hoth Therapeutics outlines its biotech pipeline as investors gauge long-term potential

    Hoth Therapeutics is advancing a portfolio of early-stage therapeutic candidates for inflammatory and dermatologic conditions. As a Nasdaq-listed biotech, its success depends on positive study outcomes, funding, and regulatory progress in a competitive landscape. The company's strategy involves building a diverse pipeline, balancing funding needs through equity financing or collaborations, and focusing on specific patient subgroups.

    Ad-hoc-news.de•7/3/26•
    Neutral

    Hoth Therapeutics shares slide after shift toward AI semiconductor strategy (HOTH)

    Hoth Therapeutics (HOTH) shares experienced a significant decline following an announcement of a strategic shift towards AI semiconductor solutions. This pivot away from its previous focus has led to investor concerns regarding dilution and the company's ability to execute this new direction.

    MSN•7/2/26•
    Bearish

    Hoth Therapeutics Inc (HOTH) Financial Health: Profitability & Balance Sheet Analysis

    This article provides an analysis of Hoth Therapeutics Inc (HOTH) financial health, focusing on profitability and balance sheet aspects. It notes that relevant financial data regarding quality of earnings, operational efficiency, growth potential, and shareholder returns have not been disclosed by the company yet. The piece displays real-time stock quotes, market capitalization, and links to further financial and analytical tools on the TradingKey platform.

    TradingKey•6/17/26•
    Neutral

    Frequently Asked Questions About HOTH

    Does HOTH pay dividends?
    HOTH (HOTH) does not currently pay a regular dividend.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In